RBC Capital analyst Daniel Busby maintained a Hold rating on Amneal Pharmaceuticals (AMRX) on May 9 and set a price target of $5.00.
The post Amneal Pharmaceuticals (AMRX) Gets a Hold Rating from RBC Capital appeared first on Smarter Analyst.
RBC Capital analyst Daniel Busby maintained a Hold rating...

https://www.smarteranalyst.com/new-blurbs/amneal-pharmaceuticals-amrx-gets-a-hold-rating-from-rbc-capital-2/

#SmarterAnalyst